Skip to main content
Top

17-06-2024 | Bronchiectasis | EDITORIAL

Type 2 Biomarkers and Bronchiectasis

Authors: Robert M. Rutherford, Micheal J. Harrison

Published in: Lung

Login to get access

Excerpt

Traditionally, bronchiectasis is considered a neutrophilic airway disorder outside of the eosinophilic etiologies asthma and allergic bronchopulmonary aspergillosis (ABPA). The ‘vicious cycle hypothesis’ of infection and airway injury mediated by unrelenting neutrophilic inflammation, with their injurious proteolytic enzymes, potent chemokines and oxidative stress, fit this paradigm very well [1]. Recent research, however, has shown that about 20% of non-asthmatic bronchiectasis patients have predominantly eosinophilic inflammation [2]. This has been demonstrated in bronchial biopsies, blood eosinophil count (BEC) ≥ 300 cells/µL and sputum (high if ≥ 3% eosinophils). In asthma and COPD, a high BEC has been shown to correlate with disease activity and increased exacerbation frequency respectively, and this may lead to treatment changes such as commencing or rationalizing the dose of inhaled corticosteroids or even adding biological therapies [3, 4]. In these conditions, the BEC has been shown to correlate with the degree of sputum eosinophilia and therefore the former can act as a surrogate for the intensity of airway eosinophilia. …
Literature
1.
go back to reference Chalmers JD, Moffitt KL, Suarez-Cuartin G et al (2017) Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 195:1384CrossRefPubMedPubMedCentral Chalmers JD, Moffitt KL, Suarez-Cuartin G et al (2017) Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med 195:1384CrossRefPubMedPubMedCentral
2.
go back to reference Tsikrika S, Dimakou K, Papaioannou AI et al (2017) The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 99:281–286CrossRefPubMed Tsikrika S, Dimakou K, Papaioannou AI et al (2017) The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis. Cytokine 99:281–286CrossRefPubMed
3.
4.
go back to reference Bhatt SP, Rabe KF, Hanania NA et al (2023) BOREAS investigators. Dupilumab for COPD with type 2 Inflammation indicated by eosinophil counts. N Engl J Med 389:205–214CrossRefPubMed Bhatt SP, Rabe KF, Hanania NA et al (2023) BOREAS investigators. Dupilumab for COPD with type 2 Inflammation indicated by eosinophil counts. N Engl J Med 389:205–214CrossRefPubMed
5.
go back to reference Shoemark A, Shteinberg M, De Soyza A et al (2022) Characterization of eosinophilic bronchiectasis: a European multicohort study. Am J Respir Crit Care Med 205:894–902CrossRefPubMed Shoemark A, Shteinberg M, De Soyza A et al (2022) Characterization of eosinophilic bronchiectasis: a European multicohort study. Am J Respir Crit Care Med 205:894–902CrossRefPubMed
6.
7.
go back to reference Ren J, Chen A, Wang J et al (2023) Association of blood total immunoglobulin E and eosinophils with radiological features of bronchiectasis. BMC Pulm Med 23:316CrossRefPubMedPubMedCentral Ren J, Chen A, Wang J et al (2023) Association of blood total immunoglobulin E and eosinophils with radiological features of bronchiectasis. BMC Pulm Med 23:316CrossRefPubMedPubMedCentral
8.
go back to reference Chen Y, Hou H, Chien N et al (2024) Type 2 Biomarkers and their clinical implications in bronchiectasis: a prospective cohort study. Lung In Press Chen Y, Hou H, Chien N et al (2024) Type 2 Biomarkers and their clinical implications in bronchiectasis: a prospective cohort study. Lung In Press
Metadata
Title
Type 2 Biomarkers and Bronchiectasis
Authors
Robert M. Rutherford
Micheal J. Harrison
Publication date
17-06-2024
Publisher
Springer US
Published in
Lung
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-024-00716-z
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare